Voya Investment Management LLC Has $24.75 Million Stock Holdings in Haemonetics Co. (NYSE:HAE)

Voya Investment Management LLC grew its position in shares of Haemonetics Co. (NYSE:HAE - Free Report) by 820.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 316,952 shares of the medical instruments supplier's stock after acquiring an additional 282,521 shares during the quarter. Voya Investment Management LLC owned 0.63% of Haemonetics worth $24,748,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Arizona State Retirement System grew its position in Haemonetics by 1.2% in the fourth quarter. Arizona State Retirement System now owns 14,853 shares of the medical instruments supplier's stock valued at $1,160,000 after purchasing an additional 181 shares in the last quarter. Parkside Financial Bank & Trust boosted its stake in shares of Haemonetics by 25.6% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier's stock worth $92,000 after buying an additional 240 shares during the last quarter. HighTower Advisors LLC grew its holdings in shares of Haemonetics by 7.8% in the 4th quarter. HighTower Advisors LLC now owns 3,353 shares of the medical instruments supplier's stock valued at $262,000 after acquiring an additional 244 shares in the last quarter. TD Waterhouse Canada Inc. acquired a new stake in shares of Haemonetics in the fourth quarter valued at about $25,000. Finally, Xponance Inc. raised its holdings in Haemonetics by 5.9% during the fourth quarter. Xponance Inc. now owns 7,246 shares of the medical instruments supplier's stock worth $566,000 after acquiring an additional 404 shares in the last quarter. 99.67% of the stock is owned by institutional investors.

Haemonetics Stock Performance

Shares of NYSE HAE traded up $1.25 during trading hours on Friday, reaching $64.24. 117,693 shares of the stock were exchanged, compared to its average volume of 687,672. The firm has a market capitalization of $3.23 billion, a price-to-earnings ratio of 25.29, a P/E/G ratio of 1.11 and a beta of 0.41. The stock's fifty day simple moving average is $62.76 and its 200 day simple moving average is $71.82. The company has a debt-to-equity ratio of 1.35, a quick ratio of 2.55 and a current ratio of 3.97. Haemonetics Co. has a 52 week low of $55.30 and a 52 week high of $97.97.

Haemonetics (NYSE:HAE - Get Free Report) last announced its earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. Sell-side analysts predict that Haemonetics Co. will post 4.55 EPS for the current year.

Analyst Ratings Changes

Several research analysts have weighed in on HAE shares. Bank of America lowered Haemonetics from a "neutral" rating to an "underperform" rating and lowered their price target for the stock from $95.00 to $68.00 in a research report on Friday, February 7th. Needham & Company LLC dropped their price target on shares of Haemonetics from $108.00 to $104.00 and set a "buy" rating on the stock in a research report on Tuesday, March 18th. Raymond James reiterated a "strong-buy" rating and issued a $115.00 price target (down previously from $120.00) on shares of Haemonetics in a research note on Friday, February 7th. StockNews.com lowered shares of Haemonetics from a "buy" rating to a "hold" rating in a research note on Saturday, February 15th. Finally, Barrington Research cut their target price on shares of Haemonetics from $108.00 to $95.00 and set an "outperform" rating for the company in a research note on Friday, February 7th. One research analyst has rated the stock with a sell rating, two have given a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $101.22.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.